Chemtrade Logistics Inc. Overview
Chemtrade is a North American industrial chemicals producer and service provider whose economics rest on essential, hard-to-substitute inorganic chemistry. It is among the continent's largest suppliers of sulphuric acid, spent (regen) acid processing, inorganic water-treatment coagulants, sodium chlorate, sodium nitrite and sodium hydrosulphite, and a leading regional supplier of sulphur, chlor-alkali products and zinc oxide. Its customers are refineries, pulp mills, municipalities, miners, food processors and semiconductor fabs that buy on reliability and logistics as much as on price. Since 2021 management has simplified the portfolio, lifted Adjusted EBITDA from $280 million to a record $507 million in 2025, eliminated all convertible debt and resumed distribution growth and buybacks. The 2025 purchases of Polytec and Thatcher's alum assets, and a new Water Solutions reporting segment in 2026, tilt the mix toward steadier water markets. Chlor-alkali cyclicality and the North Vancouver chlorine site remain the principal swing factors for earnings and sentiment.
The company's own description
In its FY2025 Annual Report, Chemtrade describes itself as a diversified business providing industrial chemicals and services to customers in North America and around the world. It claims a position as one of North America's largest suppliers of sulphuric acid, regen acid processing services, inorganic coagulants for water treatment, sodium chlorate, sodium nitrite and sodium hydrosulphite. It also describes itself as a leading regional supplier of sulphur, chlor-alkali products and zinc oxide, and as a provider of industrial services such as value-added water solutions and the processing of by-products and waste streams. By the Q2 2026 release (August 12, 2026) the description had changed in two ways. The geographic framing became "North and South America", and the company added that it is a leading producer of high-purity sulphuric acid for the North American semiconductor industry.
Independent characterization
Chemtrade is best understood as three businesses with different earnings drivers.
Acid and Sulphur Products (ASP). This is a logistics-and-processing business as much as a manufacturing one. Chemtrade takes sulphuric acid produced as a by-product by smelters, removes and markets it, manufactures acid from sulphur at its own plants, regenerates spent acid for refinery alkylation units, and upgrades acid to ultrapure grades for semiconductor fabs. A material share of volume moves under risk-sharing or cost-pass-through contracts. This is why management notes that a change in acid price affects revenue more than earnings (FY2025 MD&A). The segment also holds sodium nitrite, sodium hydrosulphite, liquid sulphur dioxide, sodium bisulphite, hydrogen sulphide, sulphides and elemental sulphur marketing.
Water Solutions (WS). This segment makes inorganic coagulants (alum, ACH, PACl and ferric sulphate) from a dense network of small regional plants. Since November 2025 it also holds Polytec's turnkey treatment-solutions business, which serves food processors and municipalities. A significant portion of WS products is sold under annual fixed-price contracts that renew on a rolling basis (Q2 2026 release). Margins therefore lag input-cost moves in both directions.
Electrochemicals (EC). This is a power-intensive commodity business with structural cost advantages. Sodium chlorate is produced at Brandon, Manitoba, which the company calls its lowest-cost source. Chlor-alkali is produced at North Vancouver, British Columbia. A sodium chlorate and chlor-alkali complex in Espírito Santo, Brazil is tied to an adjacent pulp customer. Electricity is two-thirds to three-quarters of EC variable cost and salt almost a quarter (FY2025 MD&A). Earnings are driven by the "MECU netback" (the combined realized value of caustic soda, chlorine and HCl per electrochemical unit) and by the sodium chlorate price.
Revenue model
| Dimension | Characterization | Evidence |
|---|---|---|
| Product vs. service | Predominantly product sales. Service revenue comes from regen acid processing (tolling-like), by-product removal, waste-stream processing and, since November 2025, Polytec's turnkey water solutions | FY2025 MD&A; Polytec releases |
| Subscription / licensing | None disclosed | — |
| Contract structure | Multi-year contracts with large customers; annual fixed-price contracts in water; risk-sharing supply contracts in merchant acid; index-linked caustic pricing with a one-quarter lag to the NE Asia spot index | FY2025 MD&A; Q2 2026 release |
| Customer concentration | 15 customers represent just under a quarter of revenue, concentrated in pulp and paper and oil refining | FY2025 MD&A |
| Pricing sensitivities (annual pre-tax) | Sodium chlorate ±$50/MT ≈ $13.7 million; MECU ±$100 ≈ $17.0 million; sulphuric acid ±$10/tonne ≈ $9.8 million of revenue; electricity ±4% ≈ $3.7 million; salt +$2/tonne ≈ $0.9 million; sulphur +$10/tonne ≈ $1.3 million of cost | FY2025 MD&A |
| Currency | A one-cent weakening of CAD against USD adds about $3.2 million to net earnings, $4.0 million to Adjusted EBITDA and $2.8 million to distributable cash, unhedged | FY2025 MD&A |
Value chain position and end-markets
| End-market | Products supplied | Segment |
|---|---|---|
| Petroleum refining (alkylation) | Regen acid services, sulphur, sodium bisulphite | ASP |
| Pulp and paper | Sodium chlorate, caustic soda, sodium hydrosulphite, alum | EC, ASP, WS |
| Municipal and industrial water treatment | Alum, ACH, PACl, ferric sulphate, liquid chlorine, turnkey solutions | WS, EC |
| Food processing | Polytec treatment solutions, sodium nitrite | WS, ASP |
| Semiconductors | Ultrapure sulphuric acid (Cairo, Ohio; Tulsa, Oklahoma) | ASP |
| Mining, base metals, fertilizer, industrial | Merchant sulphuric acid, by-product removal services | ASP |
| Oil and gas (fracking, upgrading) | HCl, caustic soda, sulphur services | EC, ASP |
| Rubber, coatings, heat-transfer salts | Sodium nitrite, zinc oxide | ASP |
Chemtrade sits mid-stream. Upstream it buys sulphur, by-product acid from smelters, alumina sources (hydrate, aluminum), zinc, salt and electricity. Downstream it sells into the following markets.
Strategy
Stated strategy
The FY2025 MD&A describes a strategy of growing size, scale and diversity of earnings by improving the businesses already owned, and of acquiring when it makes economic and strategic sense. Organic levers are key new products, added capacity for existing products and productivity. The Chair's 2026 letter frames value creation as operational discipline, beginning with safety, combined with thoughtful capital allocation. The CEO's recurring formulation is operational excellence, organic growth supplemented by the 2025 acquisitions, a prudent balance sheet, and returning capital through distributions and buybacks. In the Q2 2026 release Mr. Rook described guidance as reflecting "the stability of our earnings, cash flows, and balance sheet".
Vision 2030
| Element | Detail | Source |
|---|---|---|
| Launch | May 12, 2025, with Q1 2025 results | Q1 2025 release |
| Headline target | Mid-cycle Adjusted EBITDA of $550–$600 million by 2030 | Q2 2026 release |
| Growth cadence | 5–10% annual growth focus | Investor presentation summary (Quartr) |
| Means | Operational and commercial excellence; organic projects in water and ultrapure acid; acquisitions such as Polytec and Thatcher | Q2 2026 release |
| Capital returns | Distribution growth and buybacks retained alongside leverage of about 2.5x | FY2025 MD&A |
Initiatives announced in the last 24 months
| Initiative | Date | Detail | Target or status |
|---|---|---|---|
| Water solutions organic expansion | Ongoing 2024–2026 | Small capacity projects in ACH, PACl and alum; 2026 growth capex of $40–$60 million focused on water | In execution |
| Polytec acquisition | Aug 14 / Nov 21, 2025 | US$150 million; turnkey solutions platform; cross-selling in U.S. and Canada | Integration on plan |
| Thatcher Group alum assets | 2,025 | About US$30 million implied (US$180 million total less Polytec) | Integration on plan |
| Cairo, Ohio UPA expansion | 2023–2025 | US$60–65 million; first North American plant to meet next-generation node quality | Started up 2025; qualification and commercial ramp through 2026–2028 |
| Tulsa, Oklahoma UPA upgrade | 2,025 | Quality improvement upgrades | Complete; in customer certification |
| KPCT Arizona UPA joint venture | 2022 onward | Proposed plant at Casa Grande; CHIPS Act funding applied for | On hold; JV impaired $3.8 million in 2024 |
| North Vancouver long-term tenure | 2025–2026 | Port LOI (20-year term), rezoning adopted July 20, 2026; safety upgrades and new liquefaction | $75–$125 million multi-year capex; lease not yet finalized; judicial review pending |
| Capital structure optimization | Aug 2024 – Jun 2026 | $625 million of senior notes; credit facility to October 2030; all convertibles eliminated | Complete; further note refinancing under review |
| Unit buybacks | Jun 2024 onward | 8.9 million units bought in 2025 for $100.8 million; current NCIB of about 5.8 million units to April 16, 2027 | Pace moderated after Polytec |
| Distribution growth | Jan 2024, Jan 2025, Jan 2026 | +10%, +5%, +4% to $0.72 per unit annually | Three consecutive annual increases |
| U.S. investor access | Feb 20, 2026 | OTCQX listing | Complete |
| Safety programme | 2,025 | Full implementation of DuPont STOP; contractor recordables down more than 50% | OIR 0.57; top quartile |
| Segment re-reporting | Q1 2026 | WS disclosed separately | Complete |
| Technology | 2,025 | Core technology transformation; early AI adoption in back-office functions; strengthened cyber governance | Ongoing |
| Incentive redesign | 2,026 | Annual incentive refocused on distributable cash per unit | Effective 2026 |
Cost programmes and medium-term targets
No discrete cost-reduction programme with a dollar target is disclosed. Management refers to ongoing reliability, productivity and pricing initiatives and reports unplanned-downtime costs at a historic low in 2025. Financial targets are the 2026 Adjusted EBITDA range of $485–$525 million, leverage near 2.5x, a payout ratio near 40%, and the Vision 2030 EBITDA range.
Products & Services
Chemtrade does not disclose list prices, launch years for commodity products, or product-level revenue. Where a field is "not publicly disclosed", that reflects the company's disclosure practice.
Acid and Sulphur Products (ASP)
| Product / service | Description and capabilities | Target customers | Pricing model | Notes |
|---|---|---|---|---|
| Merchant sulphuric acid | Acid manufactured from sulphur at Chemtrade plants plus by-product acid removed from smelters and marketed by Chemtrade; distributed by rail, truck and vessel | Fertilizer, mining and metals, pulp, industrial and water-treatment producers | Mix of fixed-period contract pricing and risk-sharing supply contracts | A $10/tonne net price change moves North American revenue by about $9.8 million; 2025 strength came from price and volume and was the largest driver of record results |
| Regen (spent) acid processing | Regeneration of spent sulphuric acid from refinery alkylation units and return of fresh acid; several plants are pipeline-connected to or adjacent to refineries | Petroleum refiners | Long-term service contracts with cost pass-through elements | Principal sites include Beaumont (TX), Richmond (CA), Anacortes (WA), Toledo (OH), East St. Louis (IL) |
| Ultrapure sulphuric acid (UPA) | Electronic-grade acid for wafer cleaning and etching. Cairo, Ohio was expanded and upgraded (budget US$60–65 million) to meet next-generation node requirements; Tulsa, Oklahoma received quality upgrades | Semiconductor fabs | Qualification-based supply agreements; pricing not disclosed | Cairo construction and start-up completed in 2025; sales ramping to two advanced-node North American producers in H2 2026, per the Q2 2026 call summary |
| Sodium nitrite | Produced at Syracuse, New York; used in heat-transfer salts, rubber chemicals, dyes, corrosion inhibition and food curing | Industrial and food customers | Contract and spot | Described as one of North America's largest suppliers; the sodium nitrite CGU was impaired in Q2 2025; costs were higher in 2025 |
| Sodium hydrosulphite (SHS) | Reductive bleaching agent for mechanical pulp, textiles and clay; uses zinc dust feedstock | Pulp and paper, textile, minerals | Contract | Described as one of North America's largest suppliers |
| Elemental sulphur (marketing and handling) | Removal, forming, handling and marketing of refinery and gas-plant sulphur | Refiners and upgraders (supply side); acid producers (demand side) | Fee and marketing margin | Fort McMurray and Fort Saskatchewan, Alberta are principal sites |
| Liquid sulphur dioxide | Produced within the sulphur chain | Pulp, food, water treatment | Contract | Chemtrade also purchases SO2 as a raw material at some sites |
| Sodium bisulphite | Dechlorination and reducing agent | Water treatment, refining, pulp | Contract | — |
| Hydrogen sulphide and sulphides | H2S and sulphide salts; H2S is a toxic-inhalation-hazard product | Mining, chemical intermediates | Contract | — |
| Zinc oxide | Co-product of the SHS chain; Chemtrade describes itself as a leading regional supplier | Rubber, ceramics, agriculture | Contract | — |
| By-product and waste-stream processing | Removal and processing of industrial by-products and waste streams | Refining, metals and industrial generators | Service fees | Legacy Marsulex capability |
| Divested: phosphorus pentasulphide (P2S5) | Lubricant-additive intermediate | — | — | Sold November 8, 2023; contributed $40.3 million of revenue and $6.6 million of EBITDA in 2023 |
| Divested: KCl, caustic pellets, vaccine adjuvants | Specialty products | — | — | Sold Q4 2021 |
Water Solutions (WS)
| Product / service | Description and capabilities | Target customers | Pricing model | Notes |
|---|---|---|---|---|
| Aluminum sulphate (alum) | Workhorse coagulant for drinking water and wastewater clarification and for paper sizing | Municipalities, industrial water users, paper mills | Predominantly annual fixed-price contracts renewing on a rolling basis | Thatcher Group alum assets acquired in 2025 to strengthen the position |
| Aluminum chlorohydrate (ACH) | High-basicity, low-dose coagulant | Municipal and industrial | Annual contracts | Target of organic expansion capex |
| Polyaluminum chloride (PACl) | Pre-polymerized coagulant with a wide pH operating range | Municipal and industrial | Annual contracts | Target of organic expansion capex |
| Ferric sulphate | Iron-based coagulant; phosphorus and arsenic removal | Municipal and industrial | Annual contracts | — |
| Turnkey water treatment solutions (Polytec) | Chemistry plus equipment and on-site service for wastewater and process water; founded more than 30 years ago; operations in four U.S. states at announcement | Primarily food processing, also municipal | Solutions and service contracts | Acquired November 21, 2025 for US$150 million; cross-selling into Chemtrade's U.S. and Canadian footprint is the stated thesis |
Electrochemicals (EC)
| Product / service | Description and capabilities | Target customers | Pricing model | Notes |
|---|---|---|---|---|
| Sodium chlorate | Feedstock for chlorine dioxide used in elemental-chlorine-free pulp bleaching; produced at Brandon (MB), Prince George (BC) and Brazil | Bleached pulp mills | Multi-year contracts | North American volumes of 273,000 MT in 2025 and 270,000 MT in 2024; the Prince George facility was impaired in Q2 2025 |
| Caustic soda | Co-product of chlor-alkali electrolysis at North Vancouver and Brazil | Pulp and paper, alumina, water treatment, industrial | Indexed to the NE Asia spot price with a one-quarter lag | 2026 index assumption cut from US$450 to US$370 per tonne; 2025 actual US$435; 2024 US$385 |
| Chlorine (including liquid chlorine) | Co-product; liquid chlorine for municipal water disinfection | Municipal water utilities, industrial | Contract | North Vancouver supplies about 70% of the chlorine used for drinking-water purification in B.C. and Alberta (press reports); a toxic-inhalation-hazard product |
| Hydrochloric acid (HCl) | Chlorine upgraded to HCl | Oil and gas (fracking), steel, food | Spot and contract | HCl and chlorine drove about 80% of the Q2 2026 MECU netback decline |
| Brazil sodium chlorate and chlor-alkali | Two plants at one site in Espírito Santo, sharing services with an adjacent customer | Brazilian pulp producer(s) | Long-term supply | Higher revenue and margins in Q2 2026; exposed to Brazil's deregulated power market |
Aggregate North American chlor-alkali volume was 170,000 MECU in 2025 and 172,000 in 2024. The 2026 assumption was raised from 171,000 to 180,000.
Financial Narrative
IFRS; CAD millions unless stated. Sources: FY2025 Annual Report and Q4 2025 release (FY2023–FY2025); Q4 2023 release (FY2022–FY2023); FY2022 Annual Report (FY2021–FY2022); Q4 2021 release (FY2021).
Income statement
FY2021 distributions per unit reflect the $0.05 monthly rate then in force. FY2023 operating income includes the $24.3 million gain on the P2S5 sale. FY2025 operating income is after a $43.5 million PPE impairment.
Growth rates. Revenue CAGR FY2021–FY2025 is 9.9%. Adjusted EBITDA CAGR over the same period is 16.0%, consistent with the 16% cited in the company's investor presentation.
Commentary.
Revenue: The 2022 step-up of 32.5% came from pricing across both segments in a tight chlor-alkali and sulphur market. Revenue has been stable to higher since, despite the P2S5 divestiture ($40.3 million of 2023 revenue). The 2025 increase of $210.7 million was driven by merchant acid, water products and regen acid. $29.2 million was currency.
Adjusted EBITDA: The margin rose almost seven points between 2021 and 2023 and has since eased to 25.4% as mix shifted toward lower-margin acid and water revenue. Management presents about $415 million as the pre-2025 mid-cycle level and now targets $550–$600 million by 2030.
Net earnings: These are much more volatile than EBITDA because convertible debentures were carried at fair value. Fair-value changes ran through net finance costs: $26.5 million of charges in 2025 and $18.6 million in 2024. With the last convertibles redeemed in June 2026 this noise disappears. Q2 2026 net finance costs fell to $10.6 million from $35.6 million.
Tax: The 2025 effective rate was 10.4% against a 25.0% statutory rate. The main cause was recognition of previously unrecognized U.S. interest-expense carryforwards after the OBBBA enactment. This is a one-off benefit, partly offset by BEAT.
Impairments: 2021 saw the sodium chlorate impairment. 2025 saw $43.5 million for the Prince George sodium chlorate facility and the sodium nitrite CGU. 2024 saw $3.8 million for the KPCT joint venture.
Balance sheet
Short/long split: at December 31, 2025 no long-term debt principal was due within one year. The only debt-like current items were lease liabilities of $58.7 million and the fair-valued 2028 convertibles of $31.0 million. At December 31, 2024 the convertible debentures ($356.6 million at fair value) were classified as current, which explains the large IFRS working-capital deficit that year. Goodwill is not separately broken out in the sources reviewed.
June 30, 2026 update (Q2 2026 release). Long-term debt principal $1,110.8 million; debentures nil; lease liabilities $185.4 million; cash $44.5 million; net debt $1,251.7 million; net debt to LTM Adjusted EBITDA 2.55x; undrawn credit capacity about $410 million (US$289 million).
Commentary. The balance sheet story is a reshaping of the debt stack. Between 2022 and mid-2026 Chemtrade retired more than $500 million of dilutive convertible debentures and replaced them with $625 million of conventional senior notes and bank debt. It also funded US$180 million of acquisitions and more than $155 million of buybacks. Leverage rose from 1.7x to 2.55x, back to management's stated target of about 2.5x. Intangibles rose $189 million in 2025 on Polytec goodwill and customer relationships and the Thatcher customer relationships. A $66.0 million non-current income tax receivable reflects deposits with the CRA under dispute.
Cash flow
FY2025 acquisitions comprise $212.8 million for Polytec and $39.1 million of intangible assets acquired (Thatcher customer relationships). For H1 2026: operating cash flow $134.3 million; maintenance capex $71.4 million; growth capex $17.2 million; distributable cash $82.5 million ($0.7355 per unit); payout ratio 49%.
Commentary. Operating cash flow has held in a $340–$400 million band for four years. The quality of the distribution is high. In 2025 Chemtrade paid $78.9 million against $228.0 million of distributable cash and spent more on buybacks than on distributions. The first half of 2026 looks weaker because maintenance capex was front-loaded ($71.4 million against $43.9 million) and EC EBITDA fell. Management guides to a full-year payout near 40%.
Ratios
ROIC. The company defines ROIC for incentive purposes as Adjusted EBITDA divided by average debt (less lease liabilities) plus average book equity. Annual ROIC values are not publicly disclosed. The 2025–2027 PSU scale sets threshold at 11%, target at 15.75% and maximum at 17.33%. The 2023–2025 award measured a 62.6% improvement over the prior three-year average (2026 Circular). An independent estimate on that definition for FY2025, using average principal debt of about $850 million and average equity of about $797 million, gives roughly 31%. This is an EBITDA-based measure, not a post-tax NOPAT ROIC, and is not comparable to conventional ROIC.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | Period in use | Contents |
|---|---|---|
Sulphur and Water Chemicals (SWC) | Through FY2025 | Merchant, regen and ultrapure sulphuric acid; sodium hydrosulphite; elemental sulphur; hydrogen sulphide; sodium bisulphite; sulphides; processing services; alum, ACH, PACl, ferric sulphate; sodium nitrite; turnkey water solutions |
Acid and Sulphur Products (ASP) | From Q1 2026 | Merchant, regen and ultrapure acid; sodium nitrite; all other sulphur-related products; other processing services |
Water Solutions (WS) | From Q1 2026 | Inorganic coagulants (alum, ACH, PACl, ferric sulphate) and value-added water solutions (Polytec) |
Electrochemicals (EC) | Unchanged | Sodium chlorate and chlor-alkali (caustic soda, chlorine, HCl) for pulp and paper, oil and gas and water treatment; North and South America |
Corporate | Unallocated | Treasury, finance, IT, HR, legal and risk, EHS support, LTIP, hedging gains and losses |
Revenue by Segment and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 |
|---|---|---|
SWC revenue (CAD Mn) | 1,038.2 | 1,230.7 |
EC revenue (CAD Mn) | 748.9 | 767.0 |
Total revenue (CAD Mn) | 1,787.0 | 1,997.8 |
SWC gross profit (CAD Mn) | 196.7 | 198.8 |
EC gross profit (CAD Mn) | 233.8 | 261.3 |
SWC Adjusted EBITDA (CAD Mn) | 270.4 | 288.6 |
EC Adjusted EBITDA (CAD Mn) | 314.1 | 345.7 |
Corporate costs (CAD Mn) | -113.7 | -126.9 |
Total Adjusted EBITDA (CAD Mn) | 470.8 | 507.4 |
SWC Adjusted EBITDA margin (%) | 26.0 | 23.4 |
EC Adjusted EBITDA margin (%) | 41.9 | 45.1 |
SWC gross margin (%) | 19.0 | 16.2 |
EC gross margin (%) | 31.2 | 34.1 |
SWC revenue growth YoY (%) | — | 18.5 |
EC revenue growth YoY (%) | — | 2.4 |
SWC share of revenue (%) | 58.1 | 61.6 |
EC share of revenue (%) | 41.9 | 38.4 |
EC sodium chlorate volume, North America (000 MT) | 270 | 273 |
EC chlor-alkali volume, North America (000 MECU) | 172 | 170 |
Revenue by Segment and Segment Margins & Growth (%) (Quarterly)
| Metric | Q1 2025 | Q1 2026 | Q2 2025 | Q2 2026 |
|---|---|---|---|---|
ASP revenue (CAD Mn) | 153.1 | 180.3 | 163.4 | 216.4 |
WS revenue (CAD Mn) | — | — | 139.1 | 181.9 |
EC revenue (CAD Mn) | 195.3 | — | 194.2 | 180.4 |
Total revenue (CAD Mn) | 466.3 | 503.0 | 496.7 | 578.7 |
ASP Adjusted EBITDA (CAD Mn) | 36.0 | 40.2 | 43.5 | 53.2 |
WS Adjusted EBITDA (CAD Mn) | — | — | 32.7 | 37.0 |
EC Adjusted EBITDA (CAD Mn) | — | — | 92.1 | 61.2 |
Corporate costs (CAD Mn) | — | — | -30.3 | -24.1 |
Total Adjusted EBITDA (CAD Mn) | 120.1 | 113.5 | 138.0 | 127.3 |
ASP Adjusted EBITDA margin (%) | 23.5 | 22.3 | 26.6 | 24.6 |
WS Adjusted EBITDA margin (%) | — | — | 23.5 | 20.3 |
EC Adjusted EBITDA margin (%) | — | — | 47.4 | 33.9 |
Revenue by Segment
| Metric | Q4 2022 | Q4 2023 | Q4 2024 | Q4 2025 |
|---|---|---|---|---|
SWC revenue (CAD Mn) | 264.7 | 243.8 | 260.1 | 323.1 |
EC revenue (CAD Mn) | 192.0 | 178.2 | 186.4 | 179.0 |
SWC Adjusted EBITDA (CAD Mn) | 57.1 | 40.8 | 62.5 | 60.7 |
EC Adjusted EBITDA (CAD Mn) | 78.3 | 73.3 | 83.5 | 71.6 |
Corporate costs (CAD Mn) | -31.1 | -29.4 | -37.3 | -34.1 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (CAD Mn) | 1,368.5 | 1,813.4 | 1,846.8 | 1,787.0 | 1,997.8 |
Revenue growth YoY (%) | -0.8 | 32.5 | 1.8 | -3.2 | 11.8 |
Cost of sales and services (CAD Mn) | — | — | — | 1,356.5 | 1,537.7 |
Gross profit (CAD Mn) | — | — | — | 430.6 | 460.1 |
Selling and administrative expenses (CAD Mn) | — | — | — | 183.3 | 156.6 |
Operating income (CAD Mn; FY2022–FY2023 derived) | — | 219.2 | 315.4 | 243.4 | 260.0 |
Adjusted EBITDA (CAD Mn) | 280.4 | 430.9 | 502.6 | 470.8 | 507.4 |
Depreciation and amortization (CAD Mn) | — | 217.0 | 217.5 | 188.5 | 220.1 |
Net finance costs (CAD Mn) | — | 50.0 | 24.0 | 72.6 | 104.5 |
Pre-tax income (CAD Mn; FY2022–FY2023 derived) | — | 169.2 | 291.4 | 170.8 | 155.5 |
Income tax expense (CAD Mn) | — | 60.1 | 42.1 | 43.9 | 16.1 |
Net earnings (CAD Mn) | -235.2 | 109.1 | 249.3 | 126.9 | 139.4 |
Basic EPU (CAD) | -2.31 | 1.01 | 2.15 | 1.07 | 1.22 |
Diluted EPU (CAD) | -2.31 | 0.99 | 1.52 | 1.04 | 1.22 |
Distributions declared per unit (CAD) | 0.60 | 0.60 | 0.60 | 0.66 | 0.69 |
Gross margin (%) | — | — | — | 24.1 | 23.0 |
Operating margin (%) | — | 12.1 | 17.1 | 13.6 | 13.0 |
Adjusted EBITDA margin (%) | 20.5 | 23.8 | 27.2 | 26.3 | 25.4 |
Net margin (%) | -17.2 | 6.0 | 13.5 | 7.1 | 7.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansBalance Sheet
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (CAD Mn) | 2,049.0 | 2,157.1 | 2,109.2 | 2,284.4 | 2,531.3 |
Cash and equivalents (CAD Mn) | — | 72.6 | 21.5 | 25.5 | 27.4 |
Long-term debt, principal (CAD Mn) | — | 370.0 | 246.5 | 343.3 | 991.2 |
Convertible debentures, principal (CAD Mn) | — | 517.4 | 425.6 | 340.0 | 25.5 |
Total debt, principal (CAD Mn) | — | 887.4 | 672.1 | 683.3 | 1,016.8 |
Lease liabilities, current plus long-term (CAD Mn) | — | 139.6 | 179.9 | 206.4 | 191.0 |
Net debt, company definition (CAD Mn) | — | 954.5 | 830.5 | 864.2 | 1,180.3 |
Unitholders' equity (CAD Mn) | — | — | — | 818.4 | 775.1 |
Intangible assets including goodwill (CAD Mn) | — | — | — | 542.0 | 731.2 |
Property, plant and equipment (CAD Mn) | — | — | — | 1,088.1 | 1,101.0 |
Current assets (CAD Mn) | — | — | — | 334.7 | 414.4 |
Current liabilities (CAD Mn) | — | — | — | 798.0 | 462.5 |
Working capital, IFRS current assets less current liabilities (CAD Mn) | — | — | — | -463.3 | -48.1 |
Net working capital, company non-IFRS (CAD Mn) | — | — | — | -106.7 | -17.2 |
Cash Flow and Per-Share Data
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Cash flow from operating activities (CAD Mn) | 369.2 | 401.5 | 342.1 | 355.1 |
Capital expenditures (CAD Mn) | 115.4 | 166.4 | 180.1 | 176.6 |
Maintenance capex (CAD Mn) | 99.8 | 104.2 | 104.5 | 123.5 |
Growth capex (CAD Mn) | 21.6 | 62.1 | 81.3 | 48.2 |
Free cash flow, CFO less capex (CAD Mn; derived) | 253.8 | 235.1 | 162.0 | 178.5 |
Lease payments (CAD Mn) | 52.4 | 58.3 | 65.4 | 70.0 |
Cash interest (CAD Mn) | 51.7 | 42.4 | 45.7 | 54.9 |
Cash tax (CAD Mn) | 12.0 | 14.7 | 42.1 | 31.0 |
Distributable cash after maintenance capex (CAD Mn) | 215.1 | 283.0 | 213.1 | 228.0 |
Distributable cash per unit (CAD) | 1.98 | 2.44 | 1.80 | 1.99 |
Payout ratio (%) | 30 | 25 | 37 | 35 |
Distributions paid, net of DRIP (CAD Mn) | — | 58.0 | 76.6 | 78.9 |
Unit repurchases under NCIB (CAD Mn) | — | — | 54.5 | 100.8 |
Business and intangible acquisitions (CAD Mn) | — | — | 0.0 | 252.0 |
Financial Ratios (x) and Returns & Leverage Ratios (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Net debt / Adjusted EBITDA (x; company) | 2.2 | 1.7 | 1.8 | 2.3 |
Interest coverage, Adjusted EBITDA / cash interest (x; derived) | 8.3 | 11.9 | 10.3 | 9.2 |
Return on equity (%; derived, average equity) | — | — | — | 17.5 |
Return on assets (%; derived, average assets) | 5.2 | 11.7 | 5.8 | 5.8 |
Asset turnover (x; derived, average assets) | 0.86 | 0.87 | 0.81 | 0.83 |
Current ratio (x; derived) | — | — | 0.42 | 0.90 |
Total debt / equity (x; derived, principal debt) | — | — | 0.83 | 1.31 |
Cash conversion cycle (days; approximate, year-end balances) | — | — | -22 | -13 |
Segment Overview — ASP
| Segment | Canada | United States | South America |
|---|---|---|---|
ASP | Sulphur and acid services in Alberta; by-product acid from Canadian smelters | Regen plants on the Gulf Coast, West Coast and Midwest; UPA in Ohio and Oklahoma; sodium nitrite in New York | — |
WS | Coagulant plants serving Canadian municipalities | Largest coagulant network; Polytec in the U.S. Southeast; Thatcher alum assets | — |
EC | All North American production (Brandon, North Vancouver, Prince George); a meaningful share is exported to the U.S. | Sales destination only | Brazil complex: 100% of South American revenue |
Capital Markets
| Item | Value | Source |
|---|---|---|
Unit price | CAD 14.41 close on September 30; CAD 14.23 intraday on October 1 | Morningstar |
52-week range | CAD 13.18 – 18.43 | Morningstar; Yahoo |
Market capitalization | About CAD 1.60 billion | Morningstar |
Units outstanding | About 112.2 million | Morningstar |
Beta (5-year monthly) | 1.06 | Yahoo |
Annualized distribution / yield | CAD 0.72 / about 5.0% | Yahoo |
Average daily volume | About 234,000 units | Yahoo |
Number of analysts | 7 | Investing.com |
Average 12-month target | CAD 19.79 (about 37–39% above the current price) | Yahoo; Investing.com |
Target range | CAD 18.50 – 22.50 | Yahoo |
Next-year EPS consensus | CAD 1.31 | Stockopedia |
Covering brokers identified | CIBC, National Bank, Scotiabank, Desjardins, Raymond James | Call transcripts; MarketBeat |
Share Price & Returns
| Period | Performance | Source and comment |
|---|---|---|
1 year | About +6% to +9% price-only | Units traded near $13.5 in early October 2025; one aggregator cited +9.2% in early September 2026 |
3 years | The unit price rose 61% over January 1, 2023 – December 31, 2025; the price to October 2026 was not separately verified | 2026 Circular |
2026 year to date | About -3% from the December 31, 2025 close of $14.75, after a high of $18.43 | FY2025 MD&A; Morningstar |
Valuation Multiples
| Multiple | Chemtrade | Basis |
|---|---|---|
P/E (trailing) | About 11.3x | Yahoo; trailing EPU $1.27 |
P/E (normalized) | 13.0x | Morningstar |
EV / LTM Adjusted EBITDA | About 5.8x | Derived: EV about $2.85 billion; LTM Adjusted EBITDA $490.2 million |
EV / LTM sales | About 1.35x | Derived: LTM revenue about $2,116 million |
Price / book | 2.0x | Morningstar |
Price / sales | 0.77x | Morningstar |
Price / distributable cash per unit (FY2025) | About 7.2x | Derived: $14.3 / $1.99 |
Per-Share Data and Capital Markets Data (CAD)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Distributions declared per unit (CAD) | 0.60 | 0.60 | 0.60 | 0.66 | 0.69 |
Monthly rate at year-end (CAD) | 0.05 | 0.05 | 0.05 | 0.055 | 0.0575 |
Payout ratio (%) | — | 30 | 25 | 37 | 35 |
Total distributions declared (CAD Mn) | — | — | 70.1 | 78.3 | 78.9 |
Capital Programmes
| Programme | Authorization | Period | Activity |
|---|---|---|---|
2024 NCIB | Up to 11.7 million units | June 2024 – June 2, 2025 | 11.2 million units purchased |
2025 NCIB | Up to 11.2 million units | To August 18, 2026 | About 2.9 million purchased by December 31, 2025 per the MD&A's Recent Developments; 1.9 million per its Capital Allocation section and 2.8 million per the Q4 release (the sources conflict) |
Current NCIB | About 5.8 million units | Terminates April 16, 2027 | About 0.9 million bought in Q2 2026; about 4.6 million remaining at August 11, 2026 |
Credit Ratings
| Agency | Entity / instrument | Rating | Outlook | Date |
|---|---|---|---|---|
Morningstar DBRS | Chemtrade Logistics Inc. — Issuer Rating | BB (high) | Stable | Assigned August 21, 2024 |
Morningstar DBRS | Senior Unsecured Notes | BB (recovery rating RR5) | Stable | Finalized August 30, 2024 |
Moody's / S&P / Fitch | — | No rating identified | — | — |
Capital Instruments
| Instrument | Coupon | Maturity | Principal at Dec 31, 2025 (CAD Mn) | Principal at Jun 30, 2026 (CAD Mn) |
|---|---|---|---|---|
2028 Convertible Debentures | 7.00% | Jun 30, 2028 | 25.5 | 0.0 |
2028 Non-Convertible Debentures (subordinated) | 7.00% | Jun 30, 2028 | 73.9 | 73.9 |
Senior Unsecured Notes (CLI) | 6.375% | Aug 28, 2029 | 375.0 | 375.0 |
Revolving Credit Facilities (about US$600 million) | Floating; 4.2% weighted average at Dec 31, 2025 | Oct 31, 2030 | 292.3 | 411.9 |
Senior Unsecured Notes (CLI) | 5.750% | Oct 1, 2032 | 250.0 | 250.0 |
Total long-term debt principal | — | — | 991.2 | 1,110.8 |
Analyst Conclusions
Management guidance (as updated August 12, 2026)
| Item | 2026 guidance (Feb 2026) | 2026 guidance (Aug 2026) | 2025 actual | H1 2026 actual |
|---|---|---|---|---|
| Adjusted EBITDA (CAD M) | 485–525 | 485–525 | 507.4 | 240.8 |
| Maintenance capex (CAD M) | 120–150 | 130–140 | 123.5 | 71.4 |
| Growth capex (CAD M) | 35–55 | 40–60 | 48.2 | 17.2 |
| Lease payments (CAD M) | 70–80 | 70–80 | 70.0 | 35.4 |
| Cash interest (CAD M) | 65–75 | 65–75 | 54.9 | 31.9 |
| Cash tax (CAD M) | 35–45 | 30–40 | 31.0 | 19.7 |
| N.A. MECU sales volumes | 171,000 | 180,000 | 170,000 | — |
| MECU netback change vs. 2025 (CAD per MECU) | -155 | -275 | — | — |
| NE Asia caustic index (USD per tonne) | 450 | 370 | 435 | — |
| N.A. sodium chlorate production (MT) | 254,000 | 260,000 | 273,000 | — |
| USD/CAD | 1.375 | 1.375 | 1.397 | — |
| LTIP cost (CAD M) | 22–28 | 18–25 | 29.4 | — |
| Year-end net debt / EBITDA | About 2.5x | About 2.5x | 2.3x | 2.55x |
| Implied payout ratio | About 45% | About 40% | 35% | 49% |
Reading the revision. The EBITDA range is unchanged, but its composition has shifted materially. Chlor-alkali price assumptions were cut hard: caustic index down US$80 per tonne and netback down a further $120 per MECU. The offsets are higher chlor-alkali and chlorate volumes, stronger acid earnings, Polytec and lower LTIP cost. H1 delivered $240.8 million, so the midpoint requires about $264 million in H2 against $249.4 million in H2 2025. A reasonable central case is the lower half of the range.
Consensus expectations
Consensus next-year EPS is $1.31 against trailing $1.27, implying modest growth. The average price target of $19.79 implies the sell-side expects both execution toward Vision 2030 and multiple expansion. Detailed consensus EBITDA and revenue estimates are not publicly available without a subscription and are not reported.
Bull case
-
Water and UPA re-rate the mix. WS is now disclosed separately. It grew revenue 31% in Q2 2026 and should regain margin as fixed-price contracts renew. Cairo begins revenue contribution in H2 2026 and is expected to fill through 2027–2028. Both are less cyclical than EC.
-
Per-unit compounding. With no convertibles, a payout near 40% and a standing NCIB, free cash after distributions of roughly $100–$150 million a year can fund bolt-on acquisitions at about 6.5x EBITDA and retire units trading under 6x EV/EBITDA.
-
North Vancouver certainty unlocks value. The adopted bylaw converts a 2030 cliff into a horizon to as late as 2046 for an asset that supplies about 70% of Western Canada's drinking-water chlorine.
Bear case
-
EC is rolling over. Q2 2026 EC EBITDA fell $30.9 million year over year. Guidance now embeds a $275 per MECU netback decline. Sodium chlorate faces new competition and shrinking pulp demand, with Prince George already impaired.
-
Legal and capital risk at North Vancouver. A judicial review could reopen the rezoning. The port lease is still only an LOI. $75–$125 million of capex is required whatever the outcome.
-
Quality of the 2025 peak. Management itself attributes part of 2025 acid strength to external factors. Leverage is back to 2.55x. Corporate costs are high. Any shortfall against a back-half-weighted 2026 would test the credibility of the $550–$600 million 2030 target.
Catalysts and monitorables (next 12 months)
| Item | Timing | Why it matters |
|---|---|---|
| Q3 2026 results | November 11, 2026 | First test of the H2 recovery; WS margin recovery; EC netbacks |
| 2027 guidance and distribution decision | January 2027 | A fourth consecutive increase would signal confidence |
| B.C. Supreme Court proceedings on the rezoning | Late 2026 – 2027 | Binary risk to post-2030 chlorine production |
| Definitive Port Authority lease | Not dated | Converts the LOI into tenure |
| Cairo UPA qualification milestones and first volumes | H2 2026 – 2027 | Evidence for the UPA growth pillar |
| NE Asia caustic index and HCl pricing | Quarterly | Primary EC earnings driver with a one-quarter lag |
| CUSMA review outcome and U.S. tariff policy | 2,026 | Cross-border flows and alumina input costs |
| Further water acquisitions | Opportunistic | Vision 2030 inorganic component |
| Note refinancing | Opportunistic | Lower coupon and longer tenor |
| CRA tax appeal | Not dated | $66.0 million refund or write-off |
| NCIB pace | Monthly | Signals management's view of value against leverage |
Analyst verdict
Chemtrade in late 2026 is a materially better company than the over-levered, convertible-funded trust of 2020–2021, and the market only partly credits it. Over five years Adjusted EBITDA rose from $280 million to $507 million, more than $500 million of dilutive convertibles were retired, distributions were raised three times and almost nine million units were repurchased in 2025 alone. Management has also been candid: it described 2023 as above mid-cycle and flagged that 2025's acid strength was partly external. That candour gives its $485–$525 million 2026 range and $550–$600 million 2030 ambition more weight than typical targets.
The debate is about composition. Electrochemicals delivered more than half of segment EBITDA in 2025 at a 45% margin, and it is now deteriorating. Chlorine and HCl netbacks are falling, sodium chlorate faces structural pressure, and the single chlor-alkali site carries legal, lease and capital uncertainty despite July's rezoning win. Against that, Acid and Sulphur Products and Water Solutions are growing more than 30% in revenue terms, Polytec was bought at a sensible multiple, and ultrapure acid offers a credible high-return growth leg.
At roughly 5.8x EV/EBITDA, an 11x trailing P/E and a 5% yield covered more than twice, the units discount a meaningful EC decline and assign little value to the water and semiconductor options. The balance sheet at 2.55x is at target, not under-levered, so the next leg must come from earnings, not financial engineering.
The distribution appears secure. Downside is cushioned by cash generation. Upside depends on three things an investor can track: WS margin recovery, Cairo's ramp, and a clean legal outcome at North Vancouver. Failure on the third is the principal scenario that would break the thesis.
Data gaps flagged for follow-up from the FY2025 Annual Report notes and the 2025 AIF: geographic revenue split (FY2023–FY2025); FY2023 full-year segment split; FY2021–FY2023 gross profit and equity; goodwill balance; full facility list and headcount history; Summary Compensation Table totals; top institutional holders; GHG targets and ESG ratings; peer financials and multiples; date and terms of the Thatcher transaction and of the April 2026 NCIB. All figures are public-source and should be re-checked against SEDAR+ filings before investment or transactional use.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure and background | Education | Age |
|---|---|---|---|---|
Scott Rook | President and CEO; Trustee | CEO since March 1, 2021; COO September 2019 – February 2021. Previously SVP Commercial Operations at Ascend Performance Materials (2010–2019); 17 years at Eastman Chemical. Resident of Conroe, Texas | MBA (Finance), Auburn University; B.S. Industrial Engineering, University of Tennessee, Knoxville | 60 |
Rohit Bhardwaj | Chief Financial Officer | Long-serving CFO (aggregators indicate about 20 years); oversees finance, IT and legal | MBA; CMA (U.K.); FCCA (U.K.); CPA (CGA) | — |
Tim Montgomery | Group Vice-President, Manufacturing and Engineering | Leads manufacturing, engineering, Responsible Care and operational excellence | — | — |
Alan Robinson | Group Vice-President, Commercial | Leads commercial, pricing, supply chain, procurement and Brazil | — | — |
Susan Paré | General Counsel and Corporate Secretary (retired December 31, 2025) | Led legal and environmental risk | — | — |
Benjamin T. Burford | Corporate Secretary (signatory of the March 20, 2026 circular) | — | — | — |
Endri Leno | Vice President, Investor Relations | IR contact on 2026 releases | — | — |
“—” = not publicly disclosed.
Directors' Remuneration
| Executive | Base salary | Annual incentive paid (CAD) | Incentive as % of target | 2025–2027 LTI grant value (CAD) | 2023–2025 LTI realized payout (CAD) |
|---|---|---|---|---|---|
Scott Rook | USD 930,000 (CAD 1,299,610) | 2,237,266 | 143.5% | 4,173,970 | 9,294,628 |
Rohit Bhardwaj | CAD 533,000 | 495,432 | 143.0% | 880,000 | 2,725,447 |
Tim Montgomery | USD 428,500 (CAD 598,799) | 468,657 | 142.3% | 690,864 | 1,890,227 |
Susan Paré | CAD 378,200 | 269,425 | 142.5% | 385,000 | 1,055,008 |
Alan Robinson | USD 415,800 (CAD 581,051) | 403,256 | 138.8% | 647,685 | 1,702,079 |
Governance Detail
| Trustee | Role | Independent | Since | Age | Background | Committees | Equity held (units plus DSUs; value at CAD 15.00) |
|---|---|---|---|---|---|---|---|
Douglas Muzyka | Chair | Yes | Nov 13, 2020 | 71 | Former SVP and Chief Science and Technology Officer, DuPont; former head of DuPont Greater China, Canada and Mexico; director of CCL Industries and Stella-Jones; Ph.D. chemical engineering (Western Ontario) | None (Chair) | 201,902 / $3.03M |
Lucio Di Clemente | Trustee | Yes | Jul 7, 2009 | 67 | CPA, CA; corporate financial adviser; Chair of Corby Spirit and Wine; MBA (Toronto) | Audit; Governance and Nominating (chair) | 199,991 / $3.00M |
Daniella Dimitrov | Trustee | Yes | May 15, 2020 | 56 | Chief Strategy and Risk Officer, Equinox Gold; former mining CEO and CFO; director of Nexa Resources; LL.B., Global EMBA (Kellogg-Schulich) | Audit (chair); Responsible Care | 151,903 / $2.28M |
Luc Doyon | Trustee | Yes | May 10, 2022 | 66 | 34 years at Air Liquide; former CEO of Air Liquide Canada and of the group's welding division; director of Lassonde Industries and Hydro-Québec; B.Eng. (Polytechnique Montréal) | Responsible Care (chair); Human Capital and Compensation | 56,948 / $0.85M |
Gary Merasty | Trustee | Yes | Feb 20, 2024 | 61 | CEO, Peter Ballantyne Group of Companies; former MP and Grand Chief, Prince Albert Grand Council; director of Bird Construction | Human Capital and Compensation; Governance and Nominating | 27,623 / $0.41M |
Emily Moore | Trustee | Yes | Jul 1, 2019 | 56 | Director, Troost Institute, University of Toronto; formerly Hatch and Xerox; director of International Petroleum Corp.; Rhodes Scholar, D.Phil. (Oxford) | Human Capital and Compensation (chair); Governance and Nominating | 147,973 / $2.22M |
Suzann Pennington | Trustee | Yes | Jan 9, 2025 | 64 | Former Managing Director and CIO, CIBC Global Asset Management (about $110 billion); Ontario Pension Board director; CFA, B.Math (Waterloo) | Audit; Responsible Care | 26,935 / $0.40M |
Scott Rook | CEO | No | Mar 1, 2021 | 60 | See 9.1 | — | 681,382 units and RSUs / $10.22M |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
January 9, 2025 | Suzann Pennington appointed trustee | Adds capital-markets expertise |
April 1, 2025 | CEO compensation re-denominated in USD | CEO is a U.S. resident; reduces currency volatility in pay |
May 13, 2025 | Katherine Rethy retires from the board | Planned retirement |
September 4, 2025 | Committee reshuffle: Doyon to Human Capital and Compensation; Pennington to Audit | Outcome of the 2024 governance review |
December 31, 2025 | Susan Paré retires as General Counsel | Benjamin T. Burford signs as Corporate Secretary from March 2026 |
Competitive Landscape
Competitors by Segment
| Product line | Named competitors | Chemtrade's relative position |
|---|---|---|
Regen acid services | Ecovyst Inc.; Veolia North America Regeneration Services | One of the three principal North American regenerators; among the largest by its own description |
Merchant sulphuric acid | NorFalco (Glencore); Southern States Chemical; Ecovyst; smelter-direct sales | Among the largest marketers; differentiated by by-product offtake contracts and logistics |
Ultrapure sulphuric acid | PVS Chemicals; Kanto group affiliates; BASF and other Asian and European importers | Self-described leading North American producer for semiconductors |
Inorganic coagulants | USALCO; Kemira Oyj; PVS Chemicals; GEO Specialty Chemicals; Hawkins, Inc.; Holland Company; C&S Chemicals; Thatcher (remaining lines) | Among the largest North American suppliers; regional plant density is the moat |
Water treatment solutions | Hawkins, Inc.; Solenis; Ecolab (Nalco Water); Veolia Water Technologies; regional providers | New entrant through Polytec; niche in food processing in the U.S. Southeast |
Sodium chlorate | Nouryon; ERCO Worldwide; Kemira | Among the largest North American producers; Brandon is a low-cost hydro-powered asset |
Chlor-alkali | Olin Corporation; Occidental Chemical (OxyChem); Westlake Corporation; ERCO Worldwide; Shintech | Small regional producer with a strong Western Canada position, especially in liquid chlorine for water |
Sodium nitrite | Imports from BASF and Asian producers | Principal North American producer |
Sodium hydrosulphite | Imports; limited domestic competition | Among the largest North American suppliers |
Peer Comparison FY2025
| Company | Revenue | Revenue growth | EBITDA margin | Comment |
|---|---|---|---|---|
Chemtrade (FY2025) | CAD 1,997.8 million | +11.8% | 25.4% (Adjusted) | Record year |



